Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
Feng S., Bibi S., Aley PK., Cappuccini F., Clutterbuck EA., Conlin K., Ebrahimi N., Eordogh A., Faust SN., Felle S., Green J., Gill H., Mujadidi Y., Oladunjoye I., Owino N., Plested E., Robinson H., Stuart A., Voysey M., Pollard AJ., Lambe T.